胜肽治疗市场规模、份额、成长分析、按类型、按製造商、按合成技术、按给药途径、按应用、按地区 - 行业预测，2024-2031

2022年胜肽治疗市场规模估值为406.9亿美元，从2023年的431.1亿美元成长到2031年的684亿美元，预计在预测期（2024-2031年）复合年增长率为5.94%。

由于慢性病盛行率的上升和药物研发投资的增加，预计对肽疗法的需求将显着增长。随着患者和医疗保健专业人员越来越认识到这些治疗方法的低毒性，市场前景预计将进一步扩大。胜肽合成领域的创新，再加上越来越多地采用已知能够精确解决各种疾病状态的标靶治疗，预计将推动销售。癌症发生率的增加正在推动研究性胜肽疗法在肿瘤学中的使用，而政府对生物製药研究的资助揭示了该领域的新机会。然而，口服生物有效性度有限、製造成本高以及来自生技药品的竞争等挑战可能会阻碍长期成长潜力。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特分析与影响
  • 竞争公司之间的敌对关係
  • 替代品的威胁
  • 买方议价能力
  • 新进入者的威胁
  • 供应商的议价能力

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步
• 监管环境
• 案例研究
• 客户和购买标准分析

按类型分類的胜肽治疗市场规模和复合年增长率（2024-2031）

• 市场概况
• 非专利的
• 创新的

肽疗法市场规模：按製造商和复合年增长率（2024-2031）

• 市场概况
• 公司内部
• 外包

胜肽治疗市场规模：合成技术与复合年增长率（2024-2031）

• 市场概况
• 固相胜肽合成（SPPS）
• 液相肽合成（LPPS）
• 混合技术

胜肽治疗市场规模：依给药途径及复合年增长率（2024-2031）

• 市场概况
• 肠外给药
• 口服给药
• 肺
• 黏膜
• 其他的

胜肽治疗市场规模：按应用和复合年增长率（2024-2031）

• 市场概况
• 癌症
• 代谢紊乱
• 心血管疾病
• 呼吸系统疾病
• 胃肠道疾病
• 感染疾病
• 疼痛
• 皮肤病
• 神经系统疾病
• 肾臟疾病
• 其他的

肽治疗市场规模和复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC
• Sanofi SA
• GlaxoSmithKline PLC
• Novartis AG
• Zealand Pharma A/S
• AmbioPharm Inc.
• Bachem Holding AG
• PolyPeptide Group
• Circle Pharma, Inc.
• PeptiDream Inc.
• Apitope Technology Ltd.
• Ever Neuro Pharma GmbH
• Teva Pharmaceuticals Industries Ltd.
• Arch Biopartners Inc.

结论和建议

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2022 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).

The demand for peptide therapeutics is poised for significant growth driven by the escalating prevalence of chronic diseases and increased investment in drug discovery. Awareness of the low toxicity associated with these treatments among patients and healthcare professionals is likely to further enhance market prospects. Innovations in peptide synthesis are anticipated to boost sales, complemented by the rising adoption of targeted therapies known for their precision in addressing various medical conditions. The increasing incidence of cancer will catalyze the use of peptide therapeutics in oncology, while supportive government funding for biopharmaceutical research will unveil new opportunities in the sector. However, challenges such as limited oral bioavailability, high production costs, and competition from biologics may hinder long-term growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptide Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptide Therapeutics Market Segmental Analysis

Peptide Therapeutics Market is segmented by Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application and region. Based on Type, the market is segmented into Generic, Innovative. Based on Type of Manufacturers, the market is segmented into In-house, Outsourced. Based on Synthesis Technology, the market is segmented into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology. Based on Route of Administration, the market is segmented into Parenteral, Oral, Pulmonary, Mucosal, Others. Based on Application, the market is segmented into Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptide Therapeutics Market

The peptide therapeutics market is significantly driven by the increasing prevalence of chronic diseases, attributed to unhealthy lifestyle choices and habits that have become more common globally. As conditions such as diabetes and cancer continue to rise, there is an escalating demand for more effective and safer treatment options. Peptide therapeutics are particularly favored due to their low toxicity profiles, making them an appealing alternative for patients suffering from various chronic ailments. This growing recognition of peptide treatments as viable solutions underscores their importance in the evolving landscape of medical therapies, further propelling the market forward.

Restraints in the Peptide Therapeutics Market

The Peptide Therapeutics market faces significant restraints, particularly due to the limited oral bioavailability of peptides. When ingested orally, peptides are prone to degradation by digestive enzymes, which significantly restricts their effective administration in this manner. As a result, most peptide therapeutics are delivered through invasive methods like injections. However, many patients are reluctant to choose these invasive options, as they generally favor non-invasive treatment alternatives. This limitation on administration routes poses a challenge for the growth and acceptance of peptide therapeutics in the market, as it reduces patient adherence and overall treatment satisfaction.

Market Trends of the Peptide Therapeutics Market

The peptide therapeutics market is experiencing a significant trend towards the development of oral formulations, a sector currently underexploited compared to injectables. As consumer preference shifts towards non-invasive administration methods, companies that strategically invest in research to create orally bioavailable peptides stand poised to gain a competitive edge. The challenges of oral delivery, such as stability and absorption, are substantial, but the potential rewards are immense, including increased patient compliance and expanded market share. Investments in innovative drug delivery technologies and formulations could yield transformative products, propelling industry growth and establishing new standards in peptide therapeutics by 2025 and beyond.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies
• Customer & Buying Criteria Analysis

Global Peptide Therapeutics Market Size by Type & CAGR (2024-2031)

• Market Overview
• Generic
• Innovative

Global Peptide Therapeutics Market Size by Type of Manufacturers & CAGR (2024-2031)

• Market Overview
• In-house
• Outsourced

Global Peptide Therapeutics Market Size by Synthesis Technology & CAGR (2024-2031)

• Market Overview
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

Global Peptide Therapeutics Market Size by Route of Administration & CAGR (2024-2031)

• Market Overview
• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

Global Peptide Therapeutics Market Size by Application & CAGR (2024-2031)

• Market Overview
• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Others

Global Peptide Therapeutics Market Size & CAGR (2024-2031)

• North America, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • US
  • Canada
• Europe, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Type, Type of Manufacturers, Synthesis Technology, Route of Administration, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zealand Pharma A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AmbioPharm Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PolyPeptide Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Circle Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PeptiDream Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apitope Technology Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ever Neuro Pharma GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arch Biopartners Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation